* Japan Phase III: 4 only. Know that these are totally on a different level as Global Phase III's, since you would require a bunch of additional studies with global clinical trials to secure a FDA approval or EU approval abroad. That's very costly and they don't follow the pattern of other companies that conduct Japan Phase III at the same time as global trials.
* They have mostly a lot of Phase I and II compounds, which have a low success rate anyway - Maybe one out of 10 will make it.
* the indications they target are not "white space" there's already a lot of competition out there, so this is going to make for small revenues for most of them if they ever come out.
* You can see that most of the drugs in development do not come from in-house efforts. Shire/Lilly/Roche, basically they rely a lot on their ability to partner with other companies because their own portfolio is really weak.
* They are very well known in Japan to be hungry to partner with other companies since they have no blockbuster in sight internally. That's why you find them co-promoting many competitors' drugs with their reps. They are doing that recently with a ADHD drug from Shire (Intuniv) but that's just one example, there are many others (Cymbalta with Lilly, etc...)
[1] http://www.shionogi.co.jp/en/company/pmrltj0000000u4v-att/e_...